ARCHIVES

FDA Rile Changes Reporting Requirements for Adverse Events

This article is from The Cancer Letter archive.

Vol. 20 No. 44 | November 18, 1994

Download PDF Visit The Full Archive

Related Articles

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002

DCT Board Okays Consideration Of New New Heavy Particle Therapy Studies

March 8, 1985

New CEO Brings Managed Care Expertise To Network Of Academic Cancer Centers

January 24, 1997

Spartanburg CCOP Makes the List

April 10, 1987

NCI Dispute GAO Charge That Cancer Control Contracts Were Mishandled

August 15, 1980

Nominations Sought For Women’s Health Achievement AwardsFor Medical Devices

February 7, 1997